About MIRA Pharmaceuticals, Inc. - Common Stock (MIRA)
MIRA Pharmaceuticals, Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapeutic solutions for various medical conditions. The company emphasizes advancing drug development by leveraging cutting-edge technology and scientific expertise to create novel treatments. With a commitment to improving patient outcomes, MIRA Pharmaceuticals aims to address unmet medical needs through its pipeline of pharmaceutical products that target specific diseases and disorders. The company collaborates with research institutions, healthcare professionals, and other stakeholders to ensure the efficacy and safety of its offerings in the healthcare landscape. Read More
Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center
Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities
Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration
From AI-driven cancer breakthroughs and non-opioid pain innovation to 5G mmWave expansion, mining advancements , and AI-powered mobility , emerging growth stocks are igniting fresh investor momentum this week. Making headlines with major catalysts and clinical or commercial milestones that align with today’s biggest market trends in AI, biotech, clean tech, and digital transformation .
MIRA Pharmaceuticals shares are trading significantly higher on Thursday following the announcement of new preclinical data for its lead candidate Mira-55.
Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market.
